Samsung Biologics inks $262M manufacturing deal with European pharma company

The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top